Insomnia risks and costs: Health, safety, and quality of life

American Journal of Managed Care

Volumn 16, Issue 8, 2010, Pages 617-626

  Rosekind, Mark R ^a   Gregory, Kevin B ^a  

^a Alertness Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CHAMOMILE; DIPHENHYDRAMINE; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; HYDROXYZINE; MIRTAZAPINE; PRESCRIPTION DRUG; QUAZEPAM; RAMELTEON; TEMAZEPAM; TRAZODONE; TRIAZOLAM; VALERIAN; ZALEPLON; ZOLPIDEM TARTRATE;

ALCOHOL ABUSE; ALCOHOLISM; ANXIETY; ASTHMA; BIPOLAR DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DIZZINESS; DRUG USE; EMERGENCY WARD; HANGOVER; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH SERVICE; HEART DISEASE; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; INSOMNIA; LABORATORY TEST; MEMORY DISORDER; OBESITY; PRIORITY JOURNAL; PRODUCTIVITY; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; REVIEW; RISK; SAFETY; SEDATION; SIDE EFFECT; WORKPLACE;

EFFICIENCY; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; HYPNOTICS AND SEDATIVES; PUBLIC HEALTH; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SAFETY; SLEEP INITIATION AND MAINTENANCE DISORDERS; UNITED STATES; WORKPLACE;

EID: 77956117343     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. National Institutes of Health. NIH State-of-the-Science Conference: Manifestations and Management of Chronic Insomnia in Adults. June 13-15, 2005. http://consensus.nih.gov/previous.htm. Accessed June 9, 2010.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Hohagen F, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening: temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17(6):551-554.
4. Krystal AD. The effect of insomnia definitions, terminology, and classifications on clinical practice. J Am Geriatr Soc. 2005;53(7)(suppl):S258- S263.
5. National Heart, Lung, and Blood Institute and the NIH. Insomnia: key points. www.nhlbi.nih.gov/health/dci/Diseases/inso/inso-summary.html. Accessed May 2009.
6. Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123-130.
7. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
8. Keklund G, Akerstedt T. Objective components of individual differences in subjective sleep quality. J Sleep Res. 1997;6(4):217-220.
9. Roberts RE, Roberts CR, Duong HT. Chronic insomnia and its negative consequences for health and functioning of adolescents: a 12-month prospective study. J Adolesc Health. 2008;42(3):294-302.
10. Roberts RE, Roberts CR, Duong HT. Sleepless in adolescence: prospective data on sleep deprivation, health and functioning. J Adolesc. 2009;2(5):1045-1057.
11. Partinen M, Leger D, Hirshkowitz M, Chokroverty S, Hedner J. Frequency of insomnia symptoms in PCPs' patients: results of the Equinox International Survey. Paper presented at: European Sleep Research Society Meeting; September 9-13, 2008; Glasgow, Scotland.
12. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey: I. Sleep. 1999;22(suppl 2):S347-S353.
13. Grandner MA, Kripke DF. Self-reported sleep complaints with long and short sleep: a nationally representative sample. Psychosom Med. 2004;66(2):239-241.
14. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49-56.
15. National Sleep Foundation. Sleep in America Poll: data from 2002, 2003, 2004 and 2005 sleep polls. http://www.sleepfoundation.org/sites/default/files/ 2009%20Sleep%20in%20America%20SOF%20EMBARGOED.pdf. Accessed October 2009.
16. Leger D, Poursain B. An international survey of insomnia: underrecognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin. 2005;21(11):1785-1792.
17. Owens JF, Matthews KA. Sleep disturbance in healthy middle-aged women. Maturitas. 1998;30(1):41-50.
18. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425-432.
19. Webb WB. Sleep in older persons: sleep structures of 50- to 60-year-old men and women. J Gerontol. 1982;37(5):581-586.
20. Linton S, Bryngelsson I. Insomnia and its relationship to work and health in a working-age population. J Occup Rehabil. 2000;10:169-183.
21. Akerstedt T. Shift work and disturbed sleep/wakefulness. Sleep Med Rev. 1998;2(2):117-128.
22. Watson NF, Goldberg J, Arguelles L, Buchwald D. Genetic and environmental influences on insomnia, daytime sleepiness, and obesity in twins. Sleep. 2006;29(5):645-649.
23. Bastien CH, Morin CM. Familial incidence of insomnia. J Sleep Res. 2000;9(1):49-54.
24. Parry BL, Femando Martínez L, Maurer EL, López AM, Sorenson D, Meliska CJ. Sleep, rhythms and women's mood, part II: menopause. Sleep Med Rev. 2006;10(3):197-208.
25. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351-358.
26. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 National Health Interview Survey data. Arch Intern Med. 2006;166(16):1775-1782.
27. Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythms. 2006;21(6):482-493.
28. Markov D, Goldman M. Normal sleep and circadian rhythms: neurobiologic mechanisms underlying sleep and wakefulness. Psychiatr Clin North Am. 2006;29(4):841-853, abstract vii.
29. Carskadon MA, Rechtschaffen A. Monitoring and staging human sleep. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia, PA: Saunders; 2005.
30. Roth T. Measuring treatment efficacy in insomnia. J Clin Psychiatry. 2004;65(suppl 8):8-12.
31. Carskadon MA. Sleep and circadian rhythms in children and adolescents: relevance for athletic performance of young people. Clin Sports Med. 2005;24(2):319-328, x.
32. Jamison JR. Maintaining Health in Primary Care: Guidelines for Wellness in the 21st Century. Edinburgh, Scotland: Elsevier Health Sciences; 2001.
33. Gaillard JM. Is insomnia a disease of slow-wave sleep? Eur Neurol. 1976;14(6):473-484.
34. Gaillard JM. Chronic primary insomnia: possible physiopathological involvement of slow wave sleep deficiency. Sleep. 1978;1(2):133-147.
35. Merica H, Blois R, Gaillard JM. Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci. 1998;10(5):1826-1834.
36. Léger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med. 2001;63(1):49-55.
37. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959-968.
38. Winokur A, Gary KA, Rodner S, Rae-Red C, Femando AT, Szuba MP. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety. 2001;14(1):19-28.
39. Van Cauter E, Knutson KL. Sleep and the epidemic of obesity in children and adults. Eur J Endocrinol. 2008;159(suppl 1):S59-S66.
40. Smith S, Sullivan K, Hopkins W, Douglas J. Frequency of insomnia report in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). Sleep Med. 2004;5(5):449-456.
41. Brower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev. 2003;7(6):523-539.
42. Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care. 2009;15(suppl):S6-S13.
43. Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ. Comorbidity of chronic insomnia with medical problems [published correction appears in Sleep. 2007;30(7):table of contents]. Sleep. 2007;30(2):213-218.
44. Leigh TJ, Hindmarch I, Bird HA, Wright V. Comparison of sleep in osteoarthritic patients and age and sex matched healthy controls. Ann Rheum Dis. 1988;47(1):40-42.
45. Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care. 2006;12(8)(suppl):S221-S229.
46. Katz DA, McHomey CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med. 1998;158(10):1099-1107.
47. George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs. 2003;63(4):379-387.
48. Skomro RP, Ludwig S, Salamon E, Kryger MH. Sleep complaints and restless legs syndrome in adult type 2 diabetics. Sleep Med. 2001;2(5):417-422.
49. Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165(8):863-867.
50. Riemann D, Berger M, Voderholzer U. Sleep and depression: results from psychobiological studies: an overview. Biol Psychol. 2001;57(1-3):67-103.
51. Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC. Sleep problems, comorbid mental disorders, and role functioning in the National Comorbidity Survey Replication. Biol Psychiatry. 2006;60(12):1364-1371.
52. Olson LG, Cole MF, Ambrogetti A. Correlations among Epworth Sleepiness Scale scores, multiple sleep latency tests and psychological symptoms. J Sleep Res. 1998;7(4):248-253.
53. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39(6):411-418.
54. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060.
55. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(3):222-230.
56. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia: an overview. Pharmacoeconomics. 1996;10(suppl 1):1-14.
57. Nakata A, Ikeda T, Takahashi M, et al. Sleep-related risk of occupational injuries in Japanese small and medium-scale enterprises. Ind Health. 2005;43(1):89-97.
58. Akerstedt T, Fredlund P, Gillberg M, Jansson B. A prospective study of fatal occupational accidents: relationship to sleeping difficulties and occupational factors. J Sleep Res. 2002;11(1):69-71.
59. Pandi-Perumal SR, Verster JC, Kayumov L, et al. Sleep disorders, sleepiness and traffic safety: a public health menace. Braz J Med Biol Res. 2006;39(7):863-871.
60. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004;65(suppl 8):13-19.
61. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30(3):263-273.
62. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption: a study of managed-care organisation enrollees. Pharmacoeconomics. 1998;14(6):629-637.
63. National Commission on Sleep Disorders Research. Wake Up America: A National Sleep Alert: Executive Summary and Executive Report. Bethesda, MD: National Heart, Lung, and Blood Institute; 1993:1.
64. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep. 1999;22(suppl 2):S386-S393.
65. Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care. 2006;12(8) (suppl):S246-S252.
66. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16(5):873-897, 854.
67. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev. 2004;8(1):63-72.
68. Léger D, Guilleminault C, Bader G, Lévy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep. 2002;25(6):625-629.
69. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population. J Gen Intern Med. 1995;10(1):25-32.
70. Kleinman NL, Brook RA, Doan JF, Melkonian AK, Baran RW. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study. J Clin Psychiatry. 2009;70(8):1098-1104.
71. Rosekind MR, Gregory KB, Mallis MM, Brandt SL, Seal B, Lemer D. The cost of poor sleep: workplace productivity loss and associated costs. J Occup Environ Med. 2010;52(1):91-98.
72. Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009;32(1):55-64.
73. Jhaveri M, Seal B, Pollack M, Wertz D. Will insomnia treatments produce overall cost savings to commercial managed-care plans? a predictive analysis in the United States. Curr Med Res Opin. 2007;23(6):1431-1443.
74. Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep. 2009;32(6):817-824.
75. Morin AK. Strategies for treating chronic insomnia. Am J Manag Care. 2006;12(8)(suppl):S230-S245.
76. Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry. 2007;9(1):25-31.
77. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007;76(4):517-526.
78. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007;11(3):209-230.
79. Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther. 2006;112(3):612-629.
80. Becker PM. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Psychiatr Clin North Am. 2006;29(4):855-870, abstract vii.
81. Owen RT. Ramelteon: profile of a new sleep-promoting medication. Drugs Today (Barc). 2006;42(4):255-263.
82. Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7(5):397-406.
83. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. 2000;4(6):551-581.
84. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.
85. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.
86. Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy. 1996;16(4):687-689.
87. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43(4):227-238.
88. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. Travel Med Infect Dis. 2008;6(1-2):17-28.
89. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7(1):17-24.
90. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005;56(3):332-343.
91. Winokur A, DeMartinis NA III, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64(10):1224-1229.
92. Montgomery SA. Safety of mirtazapine: a review [published correction appears in Int Clin Psychopharmacol. 1996;11(2):153]. Int Clin Psychopharmacol. 1995;10(suppl 4):37-45.
93. Bon OL. Low-dose trazodone effective in insomnia [letter]. Pharmacopsychiatry. 2005;38(5):226.
94. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-476.
95. Walsh JK, Erman M, Erwin CW. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191-198.
96. White DP. Tragedy and insomnia. N Engl J Med. 2001;345(25):1846-1848.
97. Reite M, Weissberg M, Ruddy J. Clinical Manual for Evaluation and Treatment of Sleep Disorders. Washington, DC: American Psychiatric Publishing; 2008.
98. Passarella S, Duong MT. Diagnosis and treatment of insomnia. Am J Health Syst Pharm. 2008;65(10):927-934.
99. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model [published correction appears in CNS Drugs. 2006;21(5):405]. CNS Drugs. 2007;21(4):319-334.
100. Botteman M. Health economics of insomnia therapy: implications for policy. Sleep Med. 2009;10(suppl 1):S22-S25.
101. Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-976.
102. 3 agent N-(3-chlorophenyl)guanidine (MD-354) serves as a discriminative stimulus in rats and displays partial agonist character in a shrew emesis assay. Psychopharmacology (Berl). 2000;150(2):200-207.
103. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl). 1996;126(1):50-54.
104. Viola AU, Brandenberger G, Toussaint M, Bouhours P, Paul Macher J, Luthringer R. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. Clin Neurophysiol. 2002;113(3):429-434.
105. A receptor agonists. J Clin Psychiatry. 2007;68(suppl 5):6-12.
106. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol. 2006;61(6):761-766.
107. Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opin Investig Drugs. 2007;16(11):1785-1797.
108. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-627. (Pubitemid 40973437)
109. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158(12):1999-2007.
110. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60(7):427-435.
111. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-172.
112. Johnson EO, Roth T, Breslau N. The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res. 2006;40(8):700-708.
113. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. Epidemiology of insomnia, depression, and anxiety. Sleep. 2005;28(11):1457-1464.
114. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA. 1989;262(11):1479- 1484.
115. Henk HJ, Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53(10):899-904.
116. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52(10):850-856.
117. Stensland MD, Jacobson JG, Nyhuis A. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. J Affect Disord. 2007;101(1-3):187-193.
118. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398-405.
119. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165(7):820-829.
120. Rice DP. Economic costs of substance abuse, 1995. Proc Assoc Am Physicians. 1999;111(2):119-125.
121. Crum RM, Storr CL, Chan YF, Ford DE. Sleep disturbance and risk for alcohol-related problems. Am J Psychiatry. 2004;161(7):1197-1203.
122. Centers for Disease Control and Prevention. 2007 National diabetes fact sheet. http://www.cdc.gov/diabetes/pubs/estimates07.htm#10. September 2009.
123. Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm. 2008;14(1)(suppl C):S2-S14.
124. Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care. 2005;28(12):2856-2863.
125. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26(8):2300-2304.
126. Amin SP, Mullins CD, Duncan BS, Blandford L. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. Am J Health Syst Pharm. 1999;56(15):1515-1520.
127. Laliberté F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm. 2009;15(4):312-322.
128. Centers for Disease Control and Prevention. Obesity Among Adults in the United States: No Statistically Significant Change Since 2003-2004. Hyattsville, MD: National Center for Health Statistics; 2007.
129. Stone KL, Blackwell T, Ancoli-Israel S. Objective measures of sleep duration and obesity in older men and women [abstract]. Sleep. 2007;30:A106-A107.
130. Patel SR, Blackwell T, Redline S, et al; Osteoporotic Fractures in Men Research Group, Study of Osteoporotic Fractures Research Group. The association between sleep duration and obesity in older adults. Int J Obes (Lond). 2008;32(12):1825-1834.
131. Centers for Disease Control and Prevention. FastStats: Asthma. http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed August 3, 2010.
132. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497.
133. American Lung Association. Chronic obstructive pulmonary disease (COPD) fact sheet (chronic bronchitis and emphysema). http://www.ingen-tech.com/PDFbin/ COPDAmericanLun.pdf. Accessed June 10, 2010.
134. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med. 2008;102(9):1248-1256.
135. Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm. 2008;14(2):176-185.